Article
Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations.
Thoracic cancer - 1 May 2023
Zhang Ling, You Yunhong, Liu Xueli, Liu Fengjuan, Nie Keke, Ji Youxin
Abstract excerpt
BACKGROUND: The efficacy and safety of osimertinib combined with bevacizumab in non-small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) mutations have not been fully studied. METHODS: Treatment-naïve NSCLC patients with brain metastasis harboring EGFR-activating mutations were treated with osimertinib 80 mg oral daily and bevacizumab 15 mg/kg...
Topics
Join the communities discussing this publication.